Terms: = Bone cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Prognosis
5 results:
1. ZNF692 promotes osteosarcoma cell proliferation, migration, and invasion through TNK2-mediated activation of the MEK/ERK pathway.
Zheng D; Wei Z; Zhang C; Liu W; Gong C; Wu F; Guo W
Biol Direct; 2024 Apr; 19(1):28. PubMed ID: 38650011
[TBL] [Abstract] [Full Text] [Related]
2. TRIM26 inhibited osteosarcoma progression through destabilizing RACK1 and thus inactivation of MEK/ERK signaling.
Xia K; Zheng D; Wei Z; Liu W; Guo W
Cell Death Dis; 2023 Aug; 14(8):529. PubMed ID: 37591850
[TBL] [Abstract] [Full Text] [Related]
3. Clinical study of map2k1-mutated Langerhans cell histiocytosis in children.
Yang Y; Wang C; Wang D; Cui L; Li N; Lian H; Ma H; Zhao Y; Zhang L; Liu W; Wang Y; Wu W; Zhang R; Li Z; Wang T
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2517-2527. PubMed ID: 34595543
[TBL] [Abstract] [Full Text] [Related]
4. BMP4 promotes oxaliplatin resistance by an induction of epithelial-mesenchymal transition via mek1/ERK/ELK1 signaling in hepatocellular carcinoma.
Ma J; Zeng S; Zhang Y; Deng G; Qu Y; Guo C; Yin L; Han Y; Cai C; Li Y; Wang G; Bonkovsky HL; Shen H
Cancer Lett; 2017 Dec; 411():117-129. PubMed ID: 28987388
[TBL] [Abstract] [Full Text] [Related]
5. Langerhans cell histiocytosis.
Grana N
Cancer Control; 2014 Oct; 21(4):328-34. PubMed ID: 25310214
[TBL] [Abstract] [Full Text] [Related]
